MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$22,141K
Unit: Thousand (K) dollars

Income Statement
2025-12-31
General and administrative
7,585
Impairment of long-lived assets
854
Total operating expenses
8,439
Operating loss
-8,439
Non-cash (loss) gain on changes in fair value of warrant liability
24,486
Accretion of interest and amortization of discounts on convertible notes
277
Other expense, net
-20
Net loss from continuing operations
-33,222
Net income from discontinued operations, net of taxes
11,081
Net loss
-22,141
Less increase to accumulated deficit due to adjustment to common stock warrant exercise price
0
Less increase to accumulated deficit due to adjustment to preferred stock conversion price
0
Net loss attributable to common stockholders
-22,141
Basic EPS
-3.8
Basic Average Shares
5,820,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$22,141K Net loss-$22,141K Net income fromdiscontinued operations, net...$11,081K Net loss fromcontinuing operations-$33,222K Non-cash (loss) gain onchanges in fair value of...$24,486K Operating loss-$8,439K Accretion of interest andamortization of discounts on...$277K Other expense, net-$20K Total operatingexpenses$8,439K General andadministrative$7,585K Impairment of long-livedassets$854K

NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals, Inc. (NBY)